Interleukin 23 subunit alpha
Interleukin-23 subunit alpha is a protein that in humans is encoded by the IL23A gene.[1][2] IL-23 is produced by dendritic cells and macrophages.
Interleukin-23 is a heterodimeric cytokine composed of an IL-12p40 subunit that is shared with IL-12 and the IL-23p19 subunit.[1] A functional receptor for IL-23 (the IL-23 receptor) has been identified and is composed of IL-12R β1 and IL-23R.[3]
Function
IL-23 is an important part of the inflammatory response against infection. It promotes upregulation of the matrix metalloprotease MMP9, increases angiogenesis and reduces CD8+ T-cell infiltration into tumours. IL-23 mediates its effects on both innate and adaptive arms of the immune system that express the IL-23 receptor. Th17 cells represent the most prominent T cell subset that responds to IL-23, although IL-23 has been implicated in inhibiting the development of regulatory T cell development in the intestine. Th17 cells produce IL-17, a proinflammatory cytokine that enhances T cell priming and stimulates the production of other proinflammatory molecules such as IL-1, IL-6, TNF-alpha, NOS-2, and chemokines resulting in inflammation. The expression of IL23A is decreased after AHR knockdown in THP-1 cells and primary mouse macrophages http://www.ncbi.nlm.nih.gov/pubmed/26416282
Clinical significance
Knockout mice deficient in either p40 or p19, or in either subunit of the IL-23 receptor (IL-23R and IL12R-β1) develop less severe symptoms of experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel disease highlighting the importance of IL-23 in the inflammatory pathway.[4][5]
Discovery
A computational search for IL-12 homologue genes found p19, a gene that encodes a cytokine chain. Experimental work revealed that p19 formed a heterodimer by binding to p40, a subunit of IL-12. This new heterodimer was named IL-23.[6]
See also
- Ustekinumab, a monoclonal antibody targeting both IL-12 and IL-23 and used to treat plaque psoriasis, launched in the United States under the brand name Stelara
References
- 1 2 Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA (Jan 2001). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity 13 (5): 715–25. doi:10.1016/S1074-7613(00)00070-4. PMID 11114383.
- ↑ "Entrez Gene: IL23A interleukin 23, alpha subunit p19".
- ↑ Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW (2000). "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R". Journal of Immunology 168 (11): 5699–708. doi:10.4049/jimmunol.168.11.5699. PMID 12023369.
- ↑ Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M (2006). "IL-23 promotes tumour incidence and growth". Nature 442 (7101): 461–5. doi:10.1038/nature04808. PMID 16688182.
- ↑ Kikly K, Liu L, Na S, Sedgwick JD (2006). "The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation". Curr. Opin. Immunol. 18 (6): 670–5. doi:10.1016/j.coi.2006.09.008. PMID 17010592.
- ↑ Korn T, Bettelli E, Oukka M, Kuchroo VK (2009). "IL-17 and Th17 Cells". Annu. Rev. Immunol. 27: 485–517. doi:10.1146/annurev.immunol.021908.132710. PMID 19132915.
Further reading
- Lankford CS, Frucht DM (2003). "A unique role for IL-23 in promoting cellular immunity". J. Leukoc. Biol. 73 (1): 49–56. doi:10.1189/jlb.0602326. PMID 12525561.
- van de Vosse E, Lichtenauer-Kaligis EG, van Dissel JT, Ottenhoff TH (2003). "Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function". Immunogenetics 54 (12): 817–29. doi:10.1007/s00251-002-0534-9. PMID 12671732.
- Kreymborg K, Böhlmann U, Becher B (2006). "IL-23: changing the verdict on IL-12 function in inflammation and autoimmunity". Expert Opin. Ther. Targets 9 (6): 1123–36. doi:10.1517/14728222.9.6.1123. PMID 16300465.
- Peluso I, Pallone F, Monteleone G (2006). "Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication". World J. Gastroenterol. 12 (35): 5606–10. PMID 17007011.
- Prashar Y, Weissman SM (1996). "Analysis of differential gene expression by display of 3' end restriction fragments of cDNAs". Proc. Natl. Acad. Sci. U.S.A. 93 (2): 659–63. doi:10.1073/pnas.93.2.659. PMC 40108. PMID 8570611.
- Wiekowski MT, Leach MW, Evans EW, Sullivan L, Chen SC, Vassileva G, Bazan JF, Gorman DM, Kastelein RA, Narula S, Lira SA (2001). "Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death". J. Immunol. 166 (12): 7563–70. doi:10.4049/jimmunol.166.12.7563. PMID 11390512.
- Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW (2002). "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R". J. Immunol. 168 (11): 5699–708. doi:10.4049/jimmunol.168.11.5699. PMID 12023369.
- Broberg EK, Setälä N, Erälinna JP, Salmi AA, Röyttä M, Hukkanen V (2003). "Herpes simplex virus type 1 infection induces upregulation of interleukin-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice". J. Interferon Cytokine Res. 22 (6): 641–51. doi:10.1089/10799900260100123. PMID 12162874.
- Pirhonen J, Matikainen S, Julkunen I (2003). "Regulation of virus-induced IL-12 and IL-23 expression in human macrophages". J. Immunol. 169 (10): 5673–8. doi:10.4049/jimmunol.169.10.5673. PMID 12421946.
- Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW, Tao MH (2003). "Antitumor and antimetastatic activity of IL-23". J. Immunol. 171 (2): 600–7. PMID 12847224.
- Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG (2004). "Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris". J. Exp. Med. 199 (1): 125–30. doi:10.1084/jem.20030451. PMC 1887731. PMID 14707118.
- Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de Waal-Malefyt R, Ottenhoff TH (2004). "Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria". Proc. Natl. Acad. Sci. U.S.A. 101 (13): 4560–5. doi:10.1073/pnas.0400983101. PMC 384786. PMID 15070757.
- Smits HH, van Beelen AJ, Hessle C, Westland R, de Jong E, Soeteman E, Wold A, Wierenga EA, Kapsenberg ML (2004). "Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development". Eur. J. Immunol. 34 (5): 1371–80. doi:10.1002/eji.200324815. PMID 15114670.
- Schnurr M, Toy T, Shin A, Wagner M, Cebon J, Maraskovsky E (2005). "Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway". Blood 105 (4): 1582–9. doi:10.1182/blood-2004-05-1718. PMID 15486065.
|